It seems that the MEK inhibitor is at least equally effective when compared to BRAF V600E specific inhibitor in BRAF V600E mutated NSCLC and can be an alternative therapeutic option for this select group of patients. The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.